|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: COTL1 |
Gene summary for COTL1 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | COTL1 | Gene ID | 23406 |
| Gene name | coactosin like F-actin binding protein 1 | |
| Gene Alias | CLP | |
| Cytomap | 16q24.1 | |
| Gene Type | protein-coding | GO ID | GO:0002376 | UniProtAcc | Q14019 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 23406 | COTL1 | GSM4909281 | Human | Breast | IDC | 9.83e-32 | 7.82e-01 | 0.21 |
| 23406 | COTL1 | GSM4909286 | Human | Breast | IDC | 3.72e-03 | -2.36e-01 | 0.1081 |
| 23406 | COTL1 | GSM4909290 | Human | Breast | IDC | 1.25e-02 | -2.47e-01 | 0.2096 |
| 23406 | COTL1 | GSM4909297 | Human | Breast | IDC | 1.21e-05 | -2.28e-01 | 0.1517 |
| 23406 | COTL1 | GSM4909301 | Human | Breast | IDC | 3.22e-03 | -2.20e-01 | 0.1577 |
| 23406 | COTL1 | GSM4909307 | Human | Breast | IDC | 5.71e-08 | -2.84e-01 | 0.1569 |
| 23406 | COTL1 | GSM4909308 | Human | Breast | IDC | 1.35e-07 | -2.83e-01 | 0.158 |
| 23406 | COTL1 | GSM4909309 | Human | Breast | IDC | 9.13e-04 | -2.31e-01 | 0.0483 |
| 23406 | COTL1 | GSM4909311 | Human | Breast | IDC | 1.69e-10 | -2.90e-01 | 0.1534 |
| 23406 | COTL1 | GSM4909312 | Human | Breast | IDC | 3.69e-10 | -2.80e-01 | 0.1552 |
| 23406 | COTL1 | GSM4909319 | Human | Breast | IDC | 5.62e-10 | -2.53e-01 | 0.1563 |
| 23406 | COTL1 | GSM4909320 | Human | Breast | IDC | 8.65e-03 | -2.90e-01 | 0.1575 |
| 23406 | COTL1 | GSM4909321 | Human | Breast | IDC | 2.97e-07 | -2.72e-01 | 0.1559 |
| 23406 | COTL1 | brca1 | Human | Breast | Precancer | 1.01e-43 | 8.42e-01 | -0.0338 |
| 23406 | COTL1 | brca3 | Human | Breast | Precancer | 7.17e-05 | 2.62e-01 | -0.0263 |
| 23406 | COTL1 | NCCBC14 | Human | Breast | DCIS | 1.83e-03 | 2.51e-02 | 0.2021 |
| 23406 | COTL1 | NCCBC3 | Human | Breast | DCIS | 6.05e-12 | 4.79e-01 | 0.1198 |
| 23406 | COTL1 | NCCBC5 | Human | Breast | DCIS | 3.73e-12 | 4.59e-01 | 0.2046 |
| 23406 | COTL1 | P1 | Human | Breast | IDC | 6.16e-07 | -8.45e-02 | 0.1527 |
| 23406 | COTL1 | DCIS2 | Human | Breast | DCIS | 5.62e-29 | 4.52e-02 | 0.0085 |
| Page: 1 2 3 4 5 6 7 8 9 10 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Breast |  | IDC: Invasive ductal carcinoma |
| DCIS: Ductal carcinoma in situ | ||
| Precancer(BRCA1-mut): Precancerous lesion from BRCA1 mutation carriers | ||
| Cervix |  | CC: Cervix cancer |
| HSIL_HPV: HPV-infected high-grade squamous intraepithelial lesions | ||
| N_HPV: HPV-infected normal cervix | ||
| Colorectum (GSE201348) |  | FAP: Familial adenomatous polyposis |
| CRC: Colorectal cancer | ||
| Colorectum (HTA11) |  | AD: Adenomas |
| SER: Sessile serrated lesions | ||
| MSI-H: Microsatellite-high colorectal cancer | ||
| MSS: Microsatellite stable colorectal cancer | ||
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| GC |  | CAG: Chronic atrophic gastritis |
| CAG with IM: Chronic atrophic gastritis with intestinal metaplasia | ||
| CSG: Chronic superficial gastritis | ||
| GC: Gastric cancer | ||
| SIM: Severe intestinal metaplasia | ||
| WIM: Wild intestinal metaplasia | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Skin |  | AK: Actinic keratosis |
| cSCC: Cutaneous squamous cell carcinoma | ||
| SCCIS:squamous cell carcinoma in situ | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:004325420 | Oral cavity | OSCC | regulation of protein-containing complex assembly | 255/7305 | 428/18723 | 2.94e-18 | 3.15e-16 | 255 |
| GO:190290320 | Oral cavity | OSCC | regulation of supramolecular fiber organization | 211/7305 | 383/18723 | 9.45e-11 | 2.88e-09 | 211 |
| GO:005125820 | Oral cavity | OSCC | protein polymerization | 169/7305 | 297/18723 | 2.57e-10 | 7.17e-09 | 169 |
| GO:003227120 | Oral cavity | OSCC | regulation of protein polymerization | 134/7305 | 233/18723 | 7.20e-09 | 1.51e-07 | 134 |
| GO:000701520 | Oral cavity | OSCC | actin filament organization | 230/7305 | 442/18723 | 1.37e-08 | 2.77e-07 | 230 |
| GO:003297020 | Oral cavity | OSCC | regulation of actin filament-based process | 209/7305 | 397/18723 | 1.89e-08 | 3.72e-07 | 209 |
| GO:003253519 | Oral cavity | OSCC | regulation of cellular component size | 201/7305 | 383/18723 | 4.80e-08 | 8.88e-07 | 201 |
| GO:003295620 | Oral cavity | OSCC | regulation of actin cytoskeleton organization | 189/7305 | 358/18723 | 6.81e-08 | 1.21e-06 | 189 |
| GO:011005320 | Oral cavity | OSCC | regulation of actin filament organization | 150/7305 | 278/18723 | 2.68e-07 | 4.15e-06 | 150 |
| GO:000806417 | Oral cavity | OSCC | regulation of actin polymerization or depolymerization | 104/7305 | 188/18723 | 3.99e-06 | 4.66e-05 | 104 |
| GO:003083216 | Oral cavity | OSCC | regulation of actin filament length | 104/7305 | 189/18723 | 5.48e-06 | 6.14e-05 | 104 |
| GO:003083318 | Oral cavity | OSCC | regulation of actin filament polymerization | 96/7305 | 172/18723 | 5.56e-06 | 6.20e-05 | 96 |
| GO:000815418 | Oral cavity | OSCC | actin polymerization or depolymerization | 117/7305 | 218/18723 | 7.38e-06 | 8.04e-05 | 117 |
| GO:003004118 | Oral cavity | OSCC | actin filament polymerization | 103/7305 | 191/18723 | 1.94e-05 | 1.87e-04 | 103 |
| GO:0043254110 | Oral cavity | LP | regulation of protein-containing complex assembly | 163/4623 | 428/18723 | 3.72e-10 | 1.92e-08 | 163 |
| GO:0051258110 | Oral cavity | LP | protein polymerization | 113/4623 | 297/18723 | 1.90e-07 | 5.92e-06 | 113 |
| GO:0032271110 | Oral cavity | LP | regulation of protein polymerization | 89/4623 | 233/18723 | 3.00e-06 | 6.47e-05 | 89 |
| GO:1902903110 | Oral cavity | LP | regulation of supramolecular fiber organization | 131/4623 | 383/18723 | 1.58e-05 | 2.78e-04 | 131 |
| GO:0032970110 | Oral cavity | LP | regulation of actin filament-based process | 133/4623 | 397/18723 | 4.21e-05 | 6.09e-04 | 133 |
| GO:0032535110 | Oral cavity | LP | regulation of cellular component size | 128/4623 | 383/18723 | 6.56e-05 | 8.80e-04 | 128 |
| Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| COTL1 | SNV | Missense_Mutation | c.144N>G | p.Phe48Leu | p.F48L | Q14019 | protein_coding | tolerated(0.18) | benign(0.408) | TCGA-AC-A23H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD | |
| COTL1 | SNV | Missense_Mutation | c.398G>T | p.Gly133Val | p.G133V | Q14019 | protein_coding | deleterious(0) | probably_damaging(0.989) | TCGA-AD-A5EJ-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| COTL1 | SNV | Missense_Mutation | rs750865355 | c.256G>A | p.Val86Ile | p.V86I | Q14019 | protein_coding | tolerated(0.12) | benign(0.043) | TCGA-CM-4743-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Chemotherapy | capecitabine | SD |
| COTL1 | SNV | Missense_Mutation | novel | c.221N>T | p.Ser74Phe | p.S74F | Q14019 | protein_coding | tolerated(0.1) | benign(0.224) | TCGA-A5-A0G2-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
| COTL1 | SNV | Missense_Mutation | novel | c.338T>C | p.Val113Ala | p.V113A | Q14019 | protein_coding | tolerated(0.51) | benign(0.087) | TCGA-DI-A1BU-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Chemotherapy | paclitaxel | SD |
| COTL1 | SNV | Missense_Mutation | rs374406128 | c.422N>T | p.Thr141Met | p.T141M | Q14019 | protein_coding | tolerated_low_confidence(0.16) | benign(0.003) | TCGA-EO-A3KX-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| COTL1 | SNV | Missense_Mutation | c.284N>A | p.Gly95Glu | p.G95E | Q14019 | protein_coding | deleterious(0.01) | possibly_damaging(0.478) | TCGA-44-3917-01 | Lung | lung adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
| COTL1 | SNV | Missense_Mutation | rs755533045 | c.188N>C | p.Arg63Pro | p.R63P | Q14019 | protein_coding | deleterious(0) | probably_damaging(0.98) | TCGA-53-7624-01 | Lung | lung adenocarcinoma | Female | <65 | III/IV | Chemotherapy | cisplatin | PD |
| COTL1 | SNV | Missense_Mutation | rs749367597 | c.287N>T | p.Thr96Met | p.T96M | Q14019 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-55-8506-01 | Lung | lung adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| COTL1 | SNV | Missense_Mutation | rs749367597 | c.287N>T | p.Thr96Met | p.T96M | Q14019 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-CQ-A4C9-01 | Oral cavity | head & neck squamous cell carcinoma | Male | <65 | III/IV | Unknown | Unknown | PD |
| Page: 1 2 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |